Furthermore, the enhanced Notch responsiveness to DLL4 of the SIRT1-deficient lung cancer-derived ECs was abrogated by the addition of the γ-secretase inhibitor DAPT (Fig. S1C). Here, DLL4 is linked to lung carcinoma.